ARTICLE | Clinical News
BPX-601: Ph I BP-012 started
March 9, 2017 12:49 PM UTC
Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid (AP1903) in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an ame...
BCIQ Target Profiles